Clinical TrialJun 8, 2026, 09:26 AM
Polyrizon Adds 2 Clinical Sites for NASARIX (PL-14) Allergy Blocker Study
AI Summary
Polyrizon Ltd. announced it has signed agreements with two additional U.S. clinical sites for its upcoming NASARIX (PL-14) clinical study, bringing the total to three major contracted sites. These sites are strategically important and are expected to contribute significantly to patient enrollment. The study will evaluate the safety, tolerability, and efficacy of the NASARIX Allergy Blocker in patients with seasonal allergic rhinitis, marking strong execution of the company's clinical plan.
Key Highlights
- Polyrizon signed agreements with two additional U.S. clinical sites for its NASARIX (PL-14) study.
- This brings the total to three major contracted sites for the upcoming multi-center clinical trial.
- The three sites are expected to contribute the highest rates of patient enrollment.
- The study will evaluate the safety, tolerability, and efficacy of NASARIX Allergy Blocker.
- NASARIX is an intranasal hydrogel designed to create a protective barrier against airborne allergens.
- The multi-center trial in the U.S. is expected to include up to five clinical sites.
Price Impact
More from PLRZ